Your browser doesn't support javascript.
loading
Hemagglutinin-specific CD4+ T-cell responses following 2009-pH1N1 inactivated split-vaccine inoculation in humans.
Tan, Shuguang; Zhang, Shihong; Wu, Bin; Zhao, Yingze; Zhang, Wei; Han, Min; Wu, Ying; Shi, Guoli; Liu, Yingxia; Yan, Jinghua; Wu, Guizhen; Wang, Hua; Gao, George F; Zhu, Fengcai; Liu, William J.
Afiliación
  • Tan S; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China; Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People's Hospital, Shenzhen, China; Center for Influenza Research and Early-Warning (CASCIRE),
  • Zhang S; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Wu B; Jiangsu Provincial Centre for Disease Prevention and Control, Nanjing, China.
  • Zhao Y; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China.
  • Zhang W; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China.
  • Han M; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China.
  • Wu Y; School of Basic Medical Sciences, Wuhan University, No. 185 Donghu Road, Wuchang District, Wuhan, China.
  • Shi G; National Cancer Institute/HIV dynamics and replication program, Frederick, MD, USA.
  • Liu Y; Center for Influenza Research and Early-Warning (CASCIRE), Chinese Academy of Sciences, Beijing, China.
  • Yan J; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China; Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People's Hospital, Shenzhen, China; Center for Influenza Research and Early-Warning (CASCIRE),
  • Wu G; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China.
  • Wang H; Jiangsu Provincial Centre for Disease Prevention and Control, Nanjing, China.
  • Gao GF; CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, China; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China; Shenzhen Key Laborat
  • Zhu F; Jiangsu Provincial Centre for Disease Prevention and Control, Nanjing, China. Electronic address: jszfc@vip.sina.com.
  • Liu WJ; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, China; Shenzhen Key Laboratory of Pathogen and Immunity, Shenzhen Third People's Hospital, Shenzhen, China. Electronic address: liujun@ivdc.chinacdc.cn.
Vaccine ; 35(42): 5644-5652, 2017 10 09.
Article en En | MEDLINE | ID: mdl-28917539

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Linfocitos T CD4-Positivos / Vacunas de Productos Inactivados / Gripe Humana / Subtipo H1N1 del Virus de la Influenza A / Hemaglutininas Tipo de estudio: Prognostic_studies Límite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Vaccine Año: 2017 Tipo del documento: Article Pais de publicación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Linfocitos T CD4-Positivos / Vacunas de Productos Inactivados / Gripe Humana / Subtipo H1N1 del Virus de la Influenza A / Hemaglutininas Tipo de estudio: Prognostic_studies Límite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Vaccine Año: 2017 Tipo del documento: Article Pais de publicación: Países Bajos